Development of therapeutic biologics from 1984 to 2014
10.3969/j.issn.1001-1978.2015.10.007
- VernacularTitle:1984~2014年治疗性生物药物发展历程及展望
- Author:
Xin MU
;
Xiaoli TANG
;
Guanhua DU
;
Zhiang WU
- Publication Type:Journal Article
- Keywords:
US Food and Drug Administration;
therapeutic bio-logics;
biopharmaceuticals;
First-in-class;
research & develop-ment;
novel drugs
- From:
Chinese Pharmacological Bulletin
2015;(10):1356-1362
- CountryChina
- Language:Chinese
-
Abstract:
This article is to analyse the development of therapeu-tic biologics from 1984 to 2014. Data were obtained from the Drugs @ FDA, PubMed, Embase. com and ClinicalTrail. Gov. Descriptive analyses were used to classify therapeutic biologics by level of innovation,therapeutic category and the chemical na-ture of the drugs. The results showed that from 1996 the thera-peutic biologics entered the fast development period, especially from 2001 to 2005. The 125 therapeutic biologics focus on the treatment of tumor, immune system disease, endocrine and met-abolic diseases, blood system diseases, skeletal muscle system diseases. Antibody has become the dominant of therapeutic bio-logics. Antibody is widely used in the treatment of cancer, di-gestive diseases, immune diseases, respiratory diseases, urinary diseases, skeletal muscle diseases, etc.
